von Minckwitz, Gunter <br/><br/>
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.  [electronic resource] 

 -  The New England journal of medicine  Jan 2012 
 - 299-309 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1533-4406 
<br/><br/><label>Standard No.: </label>10.1056/NEJMoa1111065  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Bevacizumab<br/>Breast Neoplasms--drug therapy<br/>Cyclophosphamide--administration & dosage<br/>Disease Progression<br/>Epirubicin--administration & dosage<br/>Female<br/>Humans<br/>Logistic Models<br/>Mastectomy, Segmental<br/>Medication Adherence<br/>Middle Aged<br/>Neoadjuvant Therapy<br/>Neoplasm Staging<br/>Receptor, ErbB-2